|
1
|
Klimstra DS, Kloppel G, La Rosa S and
Rindi G: Digestive System Tumours. In: WHO Classification of
Tumours. 5th edition. Vol 1. IARC, Lyon, 2019.
|
|
2
|
Rindi G, Klimstra DS, Abedi-Ardekani B,
Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M,
El-Naggar AK, et al: A common classification framework for
neuroendocrine neoplasms: An international agency for research on
cancer (IARC) and World Health Organization (WHO) expert consensus
proposal. Mod Pathol. 31:1770–1786. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Klöppel G: Neuroendocrine neoplasms:
Dichotomy, origin and classifications. Visc Med. 33:324–330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cockburn A and Rege TA: Gastrointestinal
neuroendocrine lesions. In: Fenoglio-Preiser' Gastrointestinal
Pathology. 4th edition. Wolters Kluwer, Alphen aan den Rijn,
pp3300-3512, 2017.
|
|
5
|
Mafficini A and Scarpa A: Genetics and
epigenetics of gastroenteropancreatic neuroendocrine neoplasms.
Endocr Rev. 40:506–536. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Crona J and Skogseid B: GEP-nets update:
Genetics of neuroendocrine tumors. Eur J Endocrinol. 174:R275–R290.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cakir M, Dworakowska D and Grossman A:
Somatostatin receptor biology in neuroendocrine and pituitary
tumours: Part 1-Molecular pathways. J Cell Mol Med. 14:2570–2584.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Klomp MJ, Dalm SU, de Jong M, Feelders RA,
Hofland J and Hofland LJ: Epigenetic regulation of somatostatin and
somatostatin receptors in neuroendocrine tumors and other types of
cancer. Rev Endocr Metab Disord: Oct 21, 2020 (Epub ahead of
print).
|
|
9
|
Barbieri F, Bajetto A, Pattarozzi A, Gatti
M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M and Florio T:
Peptide receptor targeting in cancer: The somatostatin paradigm.
Int J Pept. 2013(926295)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hankus J and Tomaszewska R: Neuroendocrine
neoplasms and somatostatin receptor subtypes expression. Nucl Med
Rev Cent East Eur. 19:111–117. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tang LH, Shia J, Soslow RA, Dhall D, Wong
WD, O'Reilly E, Qin J, Paty P, Weiser MR, Guillem J, et al:
Pathologic classification and clinical behavior of the spectrum of
goblet cell carcinoid tumors of the appendix. Am J Surg Pathol.
32:1429–1443. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Taggart MW, Abraham SC, Overman MJ,
Mansfield PF and Rashid A: Goblet cell carcinoid tumor, mixed
goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the
appendix: Comparison of clinicopathologic features and prognosis.
Arch Pathol Lab Med. 139:782–790. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hristov AC, Young RH, Vang R, Yemelyanova
AV, Seidman JD and Ronnett BM: Ovarian metastases of appendiceal
tumors with goblet cell carcinoidlike and signet ring cell
patterns: A report of 30 cases. Am J Surg Pathol. 31:1502–1511.
2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Reid MD, Basturk O, Shaib WL, Xue Y, Balci
S, Choi HJ, Akkas G, Memis B, Robinson BS, El-Rayes BF, et al:
Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt
cell adenocarcinoma) is a morphologically distinct entity with
highly aggressive behavior and frequent association with
peritoneal/intra-abdominal dissemination: An analysis of 77 cases.
Mod Pathol. 29:1243–1253. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Misdraji J, Carr NJ and Pai Rk:
Appendiceal goblet cell adenocarcinoma. In: WHO Classification of
Tumours. 5th edition. Vol 1. IARC, Lyon, pp149-151, 2019.
|
|
16
|
Murnyák B and Hortobágyi T:
Immunohistochemical correlates of TP53 somatic mutations in cancer.
Oncotarget. 7:64910–64920. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nielsen K, Binderup T, Langer SW, Kjaer A,
Knigge P, Grøndahl V, Melchior L, Federspiel B and Knigge U: P53,
Somatostatin receptor 2a and Chromogranin A immunostaining as
prognostic markers in high grade gastroenteropancreatic
neuroendocrine neoplasms. BMC Cancer. 20(27)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Volante M, Brizzi MP, Faggiano A, La Rosa
S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C,
et al: Somatostatin receptor type 2A immunohistochemistry in
neuroendocrine tumors: A proposal of scoring system correlated with
somatostatin receptor scintigraphy. Mod Pathol. 20:1172–1182.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vinik AI and Chaya C: Clinical
presentation and diagnosis of neuroendocrine tumors. Hematol Oncol
Clin North Am. 30:21–48. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang R, Zheng-Pywell R, Chen HA, Bibb JA,
Chen H and Rose JB: Management of gastrointestinal neuroendocrine
tumors. Clin Med Insights Endocrinol Diabetes.
12(1179551419884058)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ito T, Sasano H, Tanaka M, Osamura RY,
Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, et al:
Epidemiological study of gastroenteropancreatic neuroendocrine
tumors in Japan. J Gastroenterol. 45:234–243. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
united states. JAMA Oncol. 3:1335–1342. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hofland J, Kaltsas G and de Herder WW:
Advances in the diagnosis and management of well-differentiated
neuroendocrine neoplasms. Endocr Rev. 41:371–403. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Scherübl H and Cadiot G: Early
gastroenteropancreatic neuroendocrine tumors: Endoscopic therapy
and surveillance. Visc Med. 33:332–338. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lewis MA and Hobday TJ: Treatment of
neuroendocrine tumor liver metastases. Int J Hepatol.
2012(973946)2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hendifar AE, Ramirez RA, Anthony LB and
Liu E: Current practices and novel techniques in the diagnosis and
management of neuroendocrine tumors of unknown primary. Pancreas.
48:1111–1118. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Calabrò D, Argalia G and Ambrosini V: Role
of PET/CT and therapy management of pancreatic neuroendocrine
tumors. Diagnostics (Basel). 10(1059)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bartsch DK and Scherübl H: Neuroendocrine
tumors of the gastrointestinal tract. Visc Med. 33:321–322.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Righi L, Volante M, Tavaglione V, Billè A,
Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G and Papotti M:
Somatostatin receptor tissue distribution in lung neuroendocrine
tumours: A clinicopathologic and immunohistochemical study of 218
‘clinically aggressive’ cases. Ann Oncol. 21:548–555.
2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Srirajaskanthan R, Watkins J, Marelli L,
Khan K and Caplin ME: Expression of somatostatin and dopamine 2
receptors in neuroendocrine tumours and the potential role for new
biotherapies. Neuroendocrinology. 89:308–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Parghane RV, Ostwal V, Ramaswamy A,
Bhandare M, Chaudhari V, Talole S, Shrikhande SV and Basu S:
Long-term outcome of 'Sandwich' chemo-PRRT: A novel treatment
strategy for metastatic neuroendocrine tumors with both FDG- and
SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging.
48:913–923. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Basu S, Parghane RV, Kamaldeep and
Chakrabarty S: Peptide receptor radionuclide therapy of
neuroendocrine tumors. Semin Nucl Med. 50:447–464. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nagtegaal ID, Klimstra DS and Washington
MK: Tumours of the appendix. Digestive System Tumours. WHO
Classification of Tumours, 5th Edition, Edited by WHO
Classification of Tumours Editorial Board, 135-156, 2019.
|
|
34
|
Kunz PL, Reidy-Lagunes D, Anthony LB,
Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK,
Klimstra DS, et al: Consensus guidelines for the management and
treatment of neuroendocrine tumors. Pancreas. 42:557–577.
2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC (eds), et al: AJCC Cancer Staging Manual (8th edition).
Springer International Publishing, New York, NY, 2017.
|
|
36
|
Papotti M, Bongiovanni M, Volante M, Allìa
E, Landolfi S, Helboe L, Schindler M, Cole SL and Bussolati G:
Expression of somatostatin receptor types 1-5 in 81 cases of
gastrointestinal and pancreatic endocrine tumors. A correlative
immunohistochemical and reverse-transcriptase polymerase chain
reaction analysis. Virchows Arch. 440:461–475. 2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
van Adrichem RC, Kamp K, van Deurzen CH,
Biermann K, Feelders RA, Franssen GJ, Kwekkeboom DJ, Hofland LJ and
de Herder WW: Is there an additional value of using somatostatin
receptor subtype 2a immunohistochemistry compared to somatostatin
receptor scintigraphy uptake in predicting gastroenteropancreatic
neuroendocrine tumor response? Neuroendocrinology. 103:560–566.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Okuwaki K, Kida M, Mikami T, Yamauchi H,
Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M,
et al: Clinicopathologic characteristics of pancreatic
neuroendocrine tumors and relation of somatostatin receptor type 2A
to outcomes. Cancer. 119:4094–4102. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue
L, Feng S, Zhou Z, Shao C, Chen M, et al: Somatostatin receptor
expression indicates improved prognosis in gastroenteropancreatic
neuroendocrine neoplasm, and octreotide long-acting release is
effective and safe in Chinese patients with advanced
gastroenteropancreatic neuroendocrine tumors. Oncol Lett.
13:1165–1174. 2017.PubMed/NCBI View Article : Google Scholar
|
